论文部分内容阅读
新氟喹诺酮具有广谱抗菌活性、口服生物利用度高、组织渗透性强以及安全性和耐受性良好等特点。基于近年来新上市的氟喹诺酮类药物抗菌谱更宽和临床用途更广 ,为了更合理的用药 ,对喹诺酮类药物重新进行分类是必要的。第一代喹诺酮 (如萘啶酸 )血药浓度低 ;第二代喹诺酮 (如环丙沙星 )对革兰氏阴性菌的抗菌谱更宽、活性更强 ;第三代喹诺酮 (如左氧氟沙星 )明显增强了对革兰氏阳性菌和非典型病原体的活性 ;第四代喹诺酮(目前只有曲伐沙星 )对厌氧菌具有明显活性。这种新的分类法有助于临床医师合理地选择使用喹诺酮类药物
The new fluoroquinolones have broad-spectrum antibacterial activity, high oral bioavailability, strong tissue permeability and good safety and tolerability. Fluoroquinolones based on the new market in recent years, the antimicrobial spectrum broader and broader clinical use, in order to more rational use of drugs, quinolones reclassified is necessary. The first generation of quinolones (such as nalidixic acid) blood concentration is low; the second generation of quinolones (such as ciprofloxacin) against Gram-negative bacteria broader antibacterial spectrum, more active; the third generation of quinolones (such as levofloxacin) The activity of Gram-positive bacteria and atypical pathogens was significantly enhanced. The fourth-generation quinolones (currently only trovafloxacin) showed obvious activity against anaerobic bacteria. This new taxonomy helps clinicians choose the quinolone drug rationally